ClinicalTrials.gg
TerminatedNCT04941404Updated Jun 3, 2026

A Study of TQ05105 Tablets in Subjects With Glucocorticoid-Refractory Acute Graft-Versus-Host Disease (aGVHD)

A Phase 1/2 interventional study of TQ05105 tablets in Glucocorticoid-Refractory aGVHD, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Terminated at 4 sites in China. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
12 Years to 75 Years
Sex
All
01

Study summary

This is an open-label,single arm,Phase Ib study,in order to evaluate the safety,tolerability, preliminary efficacy and pharmacokinetics of TQ05105 tablets in subjects with Glucocorticoid-Refractory aGVHD

02

Conditions studied

  • Glucocorticoid-Refractory aGVHD
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily participated in the study and signed an , with good compliance.
  2. Aged 12-75, gender is not limited.
  3. Subjects who has received hematopoietic stem cell transplantation (allo-HSCT) previously.
  4. Clinically suspected grades II to IV acute as per MAGIC guidelines.
  5. Drug resistance after treatment.
  6. Absolute neutrophils count (ANC) >1×109/L,(PLT)≥20×109/L within 48 hours before initial treatment.
  7. Male or female subjects should agree use an adequate method of during the study and within 6 months after the end of the study (such as intrauterine devices , contraceptives or condoms) ;No pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the first administration.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of progressive multifocal leukoencephalopathy.
  2. Subjects with many factors influencing oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction, etc.).
  3. Arteriovenous thrombotic events occurred within 6 months, such as cerebrovascular accident (including , cerebral hemorrhage, cerebral infarction), deep vein thrombosis, etc..
  4. Severe respiratory diseases (requiring mechanical ventilation or O2 saturation \< 90%), active tuberculosis, pulmonary hypertension and pulmonary embolism, etc..
  5. Subjects with a history of psychotropic drug abuse and can not quit or have mental disorders.
  6. Subjects with any severe and/or uncontrolled disease, including:

(1) Unsatisfactory blood pressure control with more than 2 drugs (systolic blood pressure ≥150mmHg or diastolic blood pressure ≥ 100mmHg) ; (2) Patients with grade ≥2 myocardial ischemia or infarction, arrhythmias (including ≥480ms), and grade ≥2 congestive heart failure ( classification); (3) Uncontrolled active infections including bacteria, fungi, parasites or viruses such ascytomegalovirus, Epstein-Barr virus, and human herpes virus 6; (4) Cirrhosis, active hepatitis; (5) (HIV) positive, active syphilis; (6) rate \< 30 mL/min,calculated by Cockcroft Gault formula; (7) Patients with epilepsy and need treatment. 7. Subjects with evidence of recurrence of primary disease or after treatment.

8. There were grade 2 or higher toxicity (except aGVHD) caused by previous allo HSCT treatment.

9. Subjects who received allo-HSCT more than once in the past. 10. Subjects who received more than one kind of systemic treatment for -Refractory aGVHD.

11. The clinical manifestations were new-onset chronic or overlapping GVHD syndrome with both acute and chronic GVHD features.

12. Allergic to the drug or its ingredients. 13. Subjects who used Janus kinase inhibitor (JAK) therapy after receiving Allo-HSCT.

14. Subjects who participated in other clinical trials within 4 weeks before initial administration.

15. According to the judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are considered unsuitable for other reasons.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    TQ05105 tablets

    Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.

    Drug: TQ05105 tablets

Interventions

  • Participants began oral administration of TQ05105 tablets at 10 mg twice daily (BID),followed by 5 mg or 15 mg BID depending on the situation of the study. twice daily in 28-day cycle until disease progression/intolerance occurs or the sponsor terminates the study.

06

What researchers measure

Primary outcomes

  1. Drug tolerance of the first cycle (Stage 1)

    Dose-limiting toxicity events related to the investigational drug occured within 28 days after initial administration

    Time frame: Day 28 after initial administration

  2. Objective Response Rate (ORR) at Day 28 (Stage 2)

    Percentage of subjects with complete response (CR) or very good partial response (VGPR) or partial response (PR) at Day 28

    Time frame: Day 28 after initial administration

Secondary outcomes

  1. CR Rate at Day 28

    Percentage of subjects with CR at Day 28

    Time frame: Day 28 after initial administration

  2. ORR at Day 28 and Day 56

    Percentage of subjects with CR or VGPR or PR at Day 28 and Day 56

    Time frame: Day 28 and Day 56 after initial administration

  3. Duration of Response (DOR)

    From date of first recorded remission to date of first recorded disease progression or date of starting any new systemic therapy for aGVHD

    Time frame: From initial administration to day 30 after the last administration

  4. Cumulative dose of glucocorticoid at Day 56

    Totally and weekly cumulative dose of glucocorticoid of each subject,from initial administration to Day 56 or the day end of therapy

    Time frame: Day 56 after initial administration

  5. Event Free Survival (EFS)

    From the date of initial administration to the date of recurrence/progression of hematological diseases or transplant failure or death from any cause

    Time frame: From initial administration to Day 30 day after the last administration

  6. Overall Survival (OS)

    Time from randomization to death

    Time frame: From initial administration to day 30 days after the last administration

  7. Incidence of Malignancy Relapse/Progression(MR),Non-Relapse Mortality(NRM)

    From the date of first administration to the date of death due to recurrence/progression of non hematological diseases; the date of recurrence or progression of hematological diseases

    Time frame: From initial administration to 30 days after the last administration

  8. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Incidence of AEs and SAEs

    Time frame: From initial administration to day 30 after the last administration

  9. Tmax

    The pharmacokinetic parameters were measured after single and multiple administration: peak time(Tmax)

    Time frame: 7 days after initial administration

  10. Cmax

    The pharmacokinetic parameters were measured after single and multiple administration: peak concentration(Cmax)

    Time frame: 7 days after initial administration

  11. AUC0-t

    The pharmacokinetic parameters were measured after single and multiple administration: area under the blood concentration-time curve (AUC0-t)

    Time frame: 7 days after initial administration

07

Study locations

4 sites
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi 530021, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215008, China
  • Hematology Hospital of the chinese Academy of Medical Sciences
    Tianjing, Tianjing 300020, China
  • The First Affiliated Hospital, College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310012, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Jul 2023, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2021
First posted
Jun 28, 2021
StartActual
Jun 10, 2022
Primary completionActual
Jul 10, 2023
CompletionActual
Dec 24, 2024
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04941404
Responsible party
Sponsor
First posted
Jun 28, 2021
Start date
Jun 10, 2022
Primary completion
Jul 10, 2023
Completion
Dec 24, 2024
Last update
Jun 3, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JAK2 Inhibitor TQ05105

Start the discussion